Close Menu

NEW YORK – OpGen announced Thursday that its subsidiary Curetis has received CE marking for its SARS-CoV-2 Kit with PULB.

The company is launching the kit in Europe. 

The RT-PCR kit qualitatively detects the virus from oropharyngeal and nasopharyngeal swabs and works with isolated RNA or swabs treated with PCR-Compatible Universal Lysis Buffer, or PULB, which is provided in the kit. Offering PULB allows labs to bypass the need for extraction equipment and reagents, OpGen said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.